Bei Akademie registrieren
Chong Kun Dang, KR7185750007

Chong Kun Dang stock secures exclusive Korea CAR-T rights

Published on 11/10/2026 at 02:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Chong Kun Dang stock will distribute Nespecel in South Korea if the CAR-T therapy wins approval. AbClon retains development and manufacturing duties.

CAR-T deal broadens oncology strategy

  • Chong Kun Dang will receive exclusive domestic distribution and hospital sales rights if Nespecel gains approval.
  • AbClon retains responsibility for trials, regulatory approval, manufacturing and supply.
  • The agreement follows Chong Kun Dang's KRW 12.2 billion investment in AbClon.
Chong Kun Dang, KR7185750007, Illustration mit AI erstellt.
Chong Kun Dang, KR7185750007, Illustration mit AI erstellt.

Chong Kun Dang has secured exclusive South Korean distribution and hospital sales rights for AbClon's Nespecel CAR-T therapy, subject to regulatory approval. AbClon announced the definitive agreement on Monday, November 9, after the contract was concluded in October, according to Seoul Economic Daily.

Exclusive rights follow investment

The agreement converts a domestic sales priority right into final commercialization rights. Chong Kun Dang secured that priority through a KRW 12.2 billion investment in AbClon in May 2025.

Chong Kun Dang will lead domestic distribution, sales and hospital marketing after approval. The companies plan to use Chong Kun Dang's oncology sales network at major tertiary hospitals and CAR-T treatment centers across South Korea.

Approval remains the next milestone

AbClon will complete the domestic clinical program, apply for product approval, manage national health insurance pricing and handle manufacturing and supply. Nespecel targets CD19 and is being developed for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

AbClon completed patient dosing in a domestic Phase 2 trial in August. The company plans to apply for conditional approval after securing final clinical data. Nespecel has also received development-stage orphan-drug designation and recognition under the Global Innovative products on Fast Track program.

The South Korean market environment is tracked through the KOSPI.

More news and analysis on Chong Kun Dang stock.

Chong Kun Dang company details

  • Company: Chong Kun Dang Pharmaceutical Corp.
  • ISIN: KR7185750007
  • Ticker: 185750.KS
  • Market: Korea Exchange
Disclaimer...
en | KR7185750007 | CHONG KUN DANG | boerse | 70483603 | bgmi